Literature DB >> 33528524

Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy.

Pankti D Reid1, Adam S Cifu1, Anne R Bass2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33528524     DOI： 10.1001/jama.2020.17308

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  8 in total

1.  Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.

Authors:  Amy Cunningham-Bussel; Jiaqi Wang; Lauren C Prisco; Lily W Martin; Kathleen M M Vanni; Alessandra Zaccardelli; Mazen Nasrallah; Lydia Gedmintas; Lindsey A MacFarlane; Nancy A Shadick; Mark M Awad; Osama Rahma; Nicole R LeBoeuf; Ellen M Gravallese; Jeffrey A Sparks
Journal:  Arthritis Rheumatol       Date:  2022-01-25       Impact factor: 10.995

2.  Immune Checkpoint Inhibitor Associated Autoimmune Encephalitis, Rare and Novel Topic of Neuroimmunology: A Case Report and Review of the Literature.

Authors:  Yining Gao; Jie Pan; Dingding Shen; Lisheng Peng; Zhifeng Mao; Chunxia Wang; Huanyu Meng; Qinming Zhou; Sheng Chen
Journal:  Brain Sci       Date:  2022-06-13

3.  Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis.

Authors:  Tina Mosaferi; Karen Tsai; Samantha Sovich; Holly Wilhalme; Nikhita Kathuria-Prakash; Stephanie S Praw; Alexandra Drakaki; Trevor E Angell; Melissa G Lechner
Journal:  Thyroid       Date:  2022-03-31       Impact factor: 6.506

4.  Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review.

Authors:  Jian Wang; Xiaoyue Xiao; Xiaorong Dong; Gang Wu; Xinghua Wang; Ruiguang Zhang
Journal:  Front Oncol       Date:  2022-08-09       Impact factor: 5.738

5.  The CURB65 score predicted 180-day mortality of non-small cell lung carcinoma patients with immune checkpoint inhibitor-associated pneumonitis: A pilot retrospective analysis.

Authors:  Fen Lan; Bo Fan; Lihua Wang; Lixia Xia; Ting Zhang; Wen Li; Yanxiong Mao
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

6.  Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study.

Authors:  Dongming Zhang; Yuequan Shi; Xiaoyan Liu; Jia Liu; Yan Xu; Jing Zhao; Wei Zhong; Lukas Käsmann; Taiki Hakozaki; Mariano Provencio; Nobuyuki Horita; Nobuhiko Fukuda; Minjiang Chen; Mengzhao Wang
Journal:  Transl Lung Cancer Res       Date:  2022-07

7.  COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.

Authors:  Rikke Boedker Holmstroem; Ole Haagen Nielsen; Søren Jacobsen; Lene Buhl Riis; Susann Theile; Jacob Tveiten Bjerrum; Peter Vilmann; Julia Sidenius Johansen; Mogens Karsbøl Boisen; Rikke Helene Løvendahl Eefsen; Inge Marie Svane; Dorte Lisbet Nielsen; Inna Markovna Chen
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

8.  Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Zijing Cai; Ping Zhan; Yong Song; Hongbing Liu; Tangfeng Lv
Journal:  Transl Lung Cancer Res       Date:  2022-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.